Ms. Bourque was previously manager of the law firm Gordon and Wise, a firm specializing in bankruptcy and reorganization. Prior to joining Gordon & Wise, Ms. Bourque was CFO of Cambridge Medical Technology Corporation, a Massachusetts based biotechnology company focused on diagnostic test kits and monoclonal antibody research and served as controller of a Boston based mid-size printing company CopyQuik Inc. In addition, Ms. Bourque was a senior public accountant for Coopers & Lybrand- (Boston) Emerging and Middle Market Group, with the biotechnology companies of Genetics Institute and Serono Laboratories as clients. Ms. Bourque also served as a NASA Space Science project manager for the first satellite payloads to be repaired by the space shuttle missions. Ms. Bourque also expanded her scientific background while working in the NH State Veterinary Diagnostic Laboratory. Ms. Bourque received her MBA degree in finance and accounting and her BS degree in veterinary medicine from the University of New Hampshire.

Ms. Bourque is a Board of Director of the Cambridge Chamber of Commerce and past Board of Director of Mayor Menino’s Boston 2000 Commission. She also is a Massachusetts Ambassador and Advisory Board Member; Member of the WGBH Corporate Executive Council and Chair of The Council of State Biomedical Associations. Ms. Bourque is Co-Founder and Co-chair of REMEDI-MA, a coalition focused on communicating and educating patients, legislators, media and the public of research and medical innovations in Massachusetts.

As a Newton resident, Ms. Bourque is a Board of Director of the Auburndale Cooperative Bank, serves as Vice President of the Newton Highlands Neighborhood Area Council and is a mayoral appointee of the Newton Biosafety Committee. An active member of St. Bernard’s Parish, she is a member of the Finance Committee, has taught Catholic Christian Doctrine for 17 years, and serves as Eucharistic Minister.

The Massachusetts Biotechnology Council (MBC), founded in 1985, is a non-for-profit organization that provides services and support for the Massachusetts biotechnology industry. The MBC is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 300 companies, academic institutions and service organizations involved in biotechnology and healthcare, the MBC works with public leaders to advance policy and promote education, while providing member programs and services.

Mara Aspinall is President of Genzyme Pharmaceuticals, a division of Genzyme Corporation. Genzyme is one of the world’s five largest biotechnology firms with more than 4000 employees and $900 million in revenue. The Pharmaceuticals Division is headquartered in Cambridge, Massachusetts with manufacturing and sales sites in the United Kingdom and Switzerland. The Division develops and manufactures novel drug products. Over the last four years, Ms. Aspinall has built an integrated international team that has created more than 25% growth in revenue and profits. Ms. Aspinall is Chairman of the Board of Genzyme Pharmaceuticals, Switzerland and serves on the Board of Delta Dental Plan of Massachusetts.

Mara was previously a Director of Client Services at Hale and Dorr LLC, responsible for the law firm’s worldwide practice development, strategic planning and marketing. She was recognized for her work in integrating technology in law firms and other service firms. Ms. Aspinall was also instrumental in the creation and publishing of The Hale and Dorr IPO Report profiling the initial public offerings market in New England and beyond.

Prior to joining Hale and Dorr, Mara was a Senior Consultant at Bain & Company, an international strategic consulting firm. In this role, she specialized in developing corporate and worldwide business strategies for healthcare product and service companies.

Ms. Aspinall is an active community leader in the Boston area. Her areas of focus are:

Ms. Aspinall received her Masters of Business Administration from Harvard Business School where she was awarded the John P. Stevens Prize for leadership. She has served on the board of the HBS Network for Women and chaired her Reunion Committee.

A magna cum laude graduate of Tufts University, Ms. Aspinall majored in international relations. She was the recipient of the Distinguished Achievement Prize. She served as President of the Association of Tufts Alumnae for five years.

The YWCA inducted Ms. Aspinall into the "Academy of Women Achievers." She was also named one of the "Ten Outstanding Young Leaders" by the Boston JayCees, in 1999. During 1998, she was chosen as one of the "Top 40 Executives under 40" by The Boston Business Journal. In 1997, she was named the "Emerging Executive of the Year" by the Greater Boston Chamber of Commerce and received the Chamber’s Pinnacle award. The Prevent Blindness Association also honored her as their "Woman of Vision" in 1996.

Genzyme Corporation is a biotechnology company that develops and markets innovative products and services for unmet medical needs. With three divisions, each targeting a specific area of expertise, Genzyme Corporation combines the resources and strengths of one of the world's largest biotechnology companies with the entrepreneurial spirit and dedication of focused, flexible, and independent businesses. Genzyme uses a wide range of technologies in its research and development efforts. With a strong international infrastructure, including extensive capabilities in sales and marketing, manufacturing, and regulatory affairs, Genzyme has a successful track record in working closely with patients and physicians. The company has three divisions: Genzyme Biosurgery, Genzyme General, and Genzyme Molecular Oncology.

Genzyme General develops and markets therapeutic products and diagnostic products and services. The division has four therapeutic products on the market and a strong pipeline of therapeutic products in development focused on the treatment of genetic disorders and other chronic debilitating diseases. Genzyme General also manufactures and markets diagnostic products, genetic testing services, and pharmaceutical intermediates. It has five operating units:

Variagenics is a leader in applying pharmacogenomics, the science that correlates genetic variations to drug response, to the creation of individualized drugs and companion molecular diagnostic products. The most commonly studied forms of genetic variability are single nucleotide polymorphisms (SNPs) that may be grouped into patterns known as haplotypes. The Company identifies clinically-relevant SNPs and haplotypes, then applies this information, along with its proprietary technologies, including its NuCleaveä genotyping/haplotyping platform, to the development of drugs and related diagnostic products that optimize therapeutic outcomes for patients, physicians and payers.

Variagenics products and services include:

ProSNP™ database

Variagenic® Impact Program (VIP)

NuCleave™ Genotyping/Haplotyping platform

Variagenic™ Targeting Program

Ms. Fisher is Founder and Former President of ViaCell, Inc. (Boston, MA). ViaCell is a privately held biotechnology company formed in April 2000. The company raised $60 million in 2000. ViaCell is a cellular medicines company delivering pharmaceutical grade cord blood stem cell products to treat cancers such as leukemia, genetic disorders and certain immune deficiencies. ViaCell combines its platform technology in stem cell amplification with its sourcing of placental and umbilical cord blood stem cells through banking services including, Viacord, a private, family cord blood banking service.

Ms. Fisher also founded ViaCord, Inc. (Boston, MA) in 1993 and was President and CEO for eight years. ViaCord provides private cord blood stem cell banking services enabling expectant parents worldwide to store their newborn’s cord blood for its potential use within their family. Ms. Fisher formerly was Marketing Manager for the Blood Bank Division of Haemonetics Corporation. She started her career in sales and marketing account management at IBM Corporation.

Ms. Fisher is Vice Chairman of the Board of Directors of the Massachusetts Biotechnology Council. She is a Trustee on the Board of Ursinus College and serves on the Board of Overseers of Duke Comprehensive Cancer Center. She is a member of the Board of Directors of ViaCell, Inc. and General Equipment Rentals, Inc. Ms. Fisher received her MBA from Harvard Business School and a B.S. in Biophysics from Ursinus College.

ViaCell is a cellular therapy company committed to providing the highest quality cellular medicines for the treatment of cancer, genetic diseases, neurological diseases, and immune deficiencies.  ViaCell's goal is to provide pharmaceutical grade stem cells derived from placental and umbilical cord blood amplified to sufficient quantities to enable widespread use of cells as therapy.

ViaCell is achieving this goal through the application of its proprietary cell expansion technology, known as Selective Amplification.  ViaCell also is recognized for ViaCord, a leading cord blood stem cell storage company. ViaCord provides both financial resources and access to cord blood, a key source material for the therapeutic business.

ViaCell was formed by the April 2000 merger of ViaCord’s (Boston, MA) cord blood stem cell banking service recognized for its comprehensive high quality service, and

t. Breeders (Worcester, MA), a clinical development-stage cellular therapy company with a patented technology platform for targeted expansion of rare cell types. Combining the capabilities of these two businesses, ViaCell is uniquely positioned to enable widespread use of cells as therapy and become the world's premier cellular pharmaceutical company.